Larimar Therapeutics IncNASDAQ:LRMR
- LAST PRICE7.6300
- TODAY'S CHANGE (%)-0.0800 (-1.0376%)
- Bid / Lots7.5100/ 2
- Ask / Lots8.7500/ 2
- Open / Previous Close7.7400 / 7.7100
- Day Range
- 52 Week Range
- Volume164,998
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LRMR |
|---|---|---|
| 09:32 ET | 4629 | 7.68 |
| 09:34 ET | 150 | 7.7467 |
| 09:36 ET | 200 | 7.7 |
| 09:39 ET | 600 | 7.7 |
| 09:41 ET | 100 | 7.69 |
| 09:43 ET | 100 | 7.69 |
| 09:45 ET | 200 | 7.71 |
| 09:48 ET | 2300 | 7.675 |
| 09:52 ET | 800 | 7.72 |
| 09:54 ET | 500 | 7.645 |
| 09:56 ET | 100 | 7.635 |
| 09:57 ET | 500 | 7.596 |
| 09:59 ET | 700 | 7.585 |
| 10:01 ET | 1100 | 7.66 |
| 10:03 ET | 100 | 7.66 |
| 10:06 ET | 100 | 7.64 |
| 10:08 ET | 100 | 7.66 |
| 10:10 ET | 400 | 7.7 |
| 10:12 ET | 100 | 7.75 |
| 10:14 ET | 388 | 7.75 |
| 10:15 ET | 1499 | 7.8 |
| 10:17 ET | 100 | 7.81 |
| 10:19 ET | 213 | 7.79 |
| 10:21 ET | 1180 | 7.77 |
| 10:24 ET | 2817 | 7.81 |
| 10:26 ET | 329 | 7.83 |
| 10:28 ET | 1400 | 7.81 |
| 10:30 ET | 563 | 7.79 |
| 10:32 ET | 2175 | 7.8 |
| 10:33 ET | 282 | 7.78 |
| 10:35 ET | 500 | 7.76 |
| 10:37 ET | 900 | 7.76 |
| 10:39 ET | 706 | 7.77 |
| 10:42 ET | 500 | 7.75 |
| 10:44 ET | 100 | 7.705 |
| 10:46 ET | 1038 | 7.67 |
| 10:48 ET | 155 | 7.6567 |
| 10:50 ET | 400 | 7.65 |
| 10:51 ET | 300 | 7.67 |
| 10:53 ET | 783 | 7.67 |
| 10:57 ET | 1620 | 7.61 |
| 11:00 ET | 400 | 7.62 |
| 11:02 ET | 100 | 7.61 |
| 11:04 ET | 400 | 7.6 |
| 11:06 ET | 2676 | 7.62 |
| 11:08 ET | 1419 | 7.64 |
| 11:09 ET | 300 | 7.67 |
| 11:11 ET | 340 | 7.655 |
| 11:13 ET | 700 | 7.69 |
| 11:15 ET | 200 | 7.715 |
| 11:20 ET | 1300 | 7.73 |
| 11:22 ET | 200 | 7.71 |
| 11:24 ET | 450 | 7.72 |
| 11:26 ET | 300 | 7.74 |
| 11:27 ET | 879 | 7.78 |
| 11:29 ET | 918 | 7.74 |
| 11:31 ET | 150 | 7.75 |
| 11:33 ET | 1100 | 7.7 |
| 11:36 ET | 100 | 7.7 |
| 11:38 ET | 300 | 7.72 |
| 11:40 ET | 900 | 7.72 |
| 11:42 ET | 1218 | 7.695 |
| 11:44 ET | 700 | 7.68 |
| 11:45 ET | 400 | 7.67 |
| 11:47 ET | 742 | 7.64 |
| 11:49 ET | 700 | 7.68 |
| 11:51 ET | 300 | 7.67 |
| 11:54 ET | 232 | 7.68 |
| 11:56 ET | 100 | 7.68 |
| 11:58 ET | 1838 | 7.69 |
| 12:00 ET | 300 | 7.7 |
| 12:03 ET | 300 | 7.7 |
| 12:05 ET | 600 | 7.71 |
| 12:07 ET | 400 | 7.7 |
| 12:09 ET | 200 | 7.71 |
| 12:12 ET | 608 | 7.71 |
| 12:14 ET | 3668 | 7.77 |
| 12:16 ET | 900 | 7.76 |
| 12:18 ET | 712 | 7.75 |
| 12:20 ET | 200 | 7.735 |
| 12:21 ET | 100 | 7.735 |
| 12:23 ET | 400 | 7.76 |
| 12:25 ET | 300 | 7.72 |
| 12:27 ET | 400 | 7.74 |
| 12:30 ET | 200 | 7.74 |
| 12:32 ET | 600 | 7.73 |
| 12:34 ET | 1464 | 7.72 |
| 12:36 ET | 716 | 7.72 |
| 12:38 ET | 1389 | 7.74 |
| 12:39 ET | 824 | 7.73 |
| 12:41 ET | 545 | 7.73 |
| 12:43 ET | 800 | 7.72 |
| 12:45 ET | 900 | 7.705 |
| 12:48 ET | 2942 | 7.675 |
| 12:50 ET | 950 | 7.655 |
| 12:52 ET | 297 | 7.64 |
| 12:54 ET | 2097 | 7.65 |
| 12:56 ET | 3364 | 7.64 |
| 12:57 ET | 4738 | 7.64 |
| 12:59 ET | 33931 | 7.63 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Larimar Therapeutics Inc | 486.8M | -7.9x | --- |
Third Harmonic Bio Inc | 489.3M | -16.0x | --- |
Lexeo Therapeutics Inc | 490.6M | -5.5x | --- |
Astria Therapeutics Inc | 494.2M | -3.9x | --- |
Kalvista Pharmaceuticals Inc | 494.4M | -3.7x | --- |
Annexon Inc | 496.2M | -3.3x | --- |
Company Information
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. It intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Contact Information
- Headquarters
- THREE BALA PLAZA EAST. SUITE 506BALA CYNWYD, PA, United States 19004
- Phone
- 617-622-4003
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Joseph Truitt
- President, Chief Executive Officer, Director
- Carole Ben-Maimon
- Chief Financial Officer, Secretary
- Michael Celano
- Chief Medical Officer
- Russell Clayton
- Chief Development Officer
- Gopi Shankar
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $486.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 63.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.01 |
EPS | $-0.97 |
Book Value | $1.86 |
P/E Ratio | -7.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
